TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 221114

Group type: EXPERIMENTAL
Intervention: Cyclic alternating combination chemotherapy with high‐dose cyclophosphamide, methotrexate, and CCNU (CMC) followed by vincristine, adriamycin, and procarbazine (VAP) for 6 weeks each.
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Addition of VAP after CMC treatment.
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Addition of VO‐16‐213 and ifosfamide for half of the patients.
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Complete responders only.
Number of subjects: 61
Study: 30278430

Group type: EXPERIMENTAL
Intervention: Resveratrol 100 mg/d
Number of subjects: 71

Group type: COMPARATOR
Intervention: Placebo (sucrose 0.5 g/d)
Number of subjects: 71
Study: 28598661

Group type: EXPERIMENTAL
Intervention: Barrier control
Number of subjects: 0

Group type: COMPARATOR
Intervention: Tilt control
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Barrier control with optimized composite pulses
Number of subjects: 0
Study: 25761202

Group type: EXPERIMENTAL
Intervention: Continuous glucose monitoring (CGM) data analysis
Number of subjects: 45
Study: 23328268

Group type: EXPERIMENTAL
Intervention: Clopidogrel napadisilate plus aspirin
Number of subjects: 127

Group type: COMPARATOR
Intervention: Clopidogrel bisulfate plus aspirin
Number of subjects: 127
Study: 22026966

Group type: EXPERIMENTAL
Intervention: Combined diet + exercise
Number of subjects: 439

Group type: EXPERIMENTAL
Intervention: Diet
Number of subjects: 439

Group type: COMPARATOR
Intervention: Exercise
Number of subjects: 439

Group type: COMPARATOR
Intervention: Control
Number of subjects: 439
Study: 19210039

Group type: EXPERIMENTAL
Intervention: SLDT and ISW
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Other methods of assessing premorbid cognitive function
Number of subjects: 0
Study: 16580587

Group type: EXPERIMENTAL
Intervention: Pistachio diet (substituting pistachio nuts for 20% of daily caloric intake for 3 weeks)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Regular diet
Number of subjects: 44
Study: 14508717

Group type: EXPERIMENTAL
Intervention: Pegfilgrastim (Neulasta)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Filgrastim (r‐metHuG‐CSF)
Number of subjects: 0
Study: 10902094

Group type: EXPERIMENTAL
Intervention: Clonidine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Psychostimulants
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Haloperidol
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Risperidone
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Nalfrexone
Number of subjects: 0

Group type: COMPARATOR
Intervention: Secretin
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Serotonin-reuptake inhibitors
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Buspirone, mood stabilizers, beta-blockers
Number of subjects: 0
Study: 9229615

Group type: EXPERIMENTAL
Intervention: Cordipin chronotherapy (10 mg once a day based on chronosensitivity)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Conventional treatment with cordipin (10 mg 3 times a day)
Number of subjects: 40
Study: 8447919

Group type: EXPERIMENTAL
Intervention: Five-minute stations
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Ten-minute stations
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Checklist subscores
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Couplet subscores
Number of subjects: 36
Study: 2934557

Group type: EXPERIMENTAL
Intervention: 500 mg adjuvant medroxyprogesterone 3 times a week for 1 year
Number of subjects: 136

Group type: COMPARATOR
Intervention: No treatment (control group)
Number of subjects: 136
Study: 28557043

Group type: EXPERIMENTAL
Intervention: Nurse-led psychological intervention programme (seven weekly counselling sessions)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 60
Study: 26578543

Group type: EXPERIMENTAL
Intervention: Intensive lifestyle intervention (ILI) for weight loss
Number of subjects: 3214

Group type: COMPARATOR
Intervention: Diabetes mellitus support and education
Number of subjects: 3214
Study: 25550013

Group type: EXPERIMENTAL
Intervention: Autologous blood injection (2 ml of autologous venous blood mixed with 1 ml of 2% prilocaine hydrochloride)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Corticosteroid injection (1 ml of 40 mg methylprednisolone acetate mixed with 1 ml of 2% prilocaine hydrochloride)
Number of subjects: 80
Study: 22413836

Group type: EXPERIMENTAL
Intervention: Atenolol
Number of subjects: 499

Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide
Number of subjects: 499

Group type: EXPERIMENTAL
Intervention: Weighted averages of all four methods
Number of subjects: 499

Group type: COMPARATOR
Intervention: Office BP measurement
Number of subjects: 499

Group type: COMPARATOR
Intervention: Ambulatory nighttime BP measurement
Number of subjects: 499
Study: 20511285

Group type: EXPERIMENTAL
Intervention: Internet-based CBT intervention
Number of subjects: 96

Group type: COMPARATOR
Intervention: Waiting-list control condition
Number of subjects: 96
Study: 18456384

Group type: EXPERIMENTAL
Intervention: Laparoscopic hysterectomy
Number of subjects: 125

Group type: COMPARATOR
Intervention: Abdominal hysterectomy
Number of subjects: 125

Group type: EXPERIMENTAL
Intervention: Stress-coping ability (measured preoperatively)
Number of subjects: 125

Group type: EXPERIMENTAL
Intervention: Postoperative complications
Number of subjects: 125

Group type: EXPERIMENTAL
Intervention: Stress-coping ability
Number of subjects: 125
Study: 14709512

Group type: EXPERIMENTAL
Intervention: Body composition measurement using dual energy x ray absorptiometry (DEXA) and bioelectrical impedance analysis (BIA)
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Bioelectrical impedance analysis (BIA)
Number of subjects: 35
Study: 11732218

Group type: EXPERIMENTAL
Intervention: Nd-YAG laser capsulotomy
Number of subjects: 54

Group type: COMPARATOR
Intervention: Topical Beta-blockers and steroids
Number of subjects: 54
Study: 9126899

Group type: EXPERIMENTAL
Intervention: Transluminal angioplasty
Number of subjects: 14

Group type: COMPARATOR
Intervention: Intraarterial papaverine (compared with no papaverine)
Number of subjects: 14
Study: 7952921

Group type: COMPARATOR
Intervention: Lymphocyte transformation assay for serovar A
Number of subjects: 20

Group type: COMPARATOR
Intervention: Lymphocyte transformation assay for serovar B
Number of subjects: 20

Group type: COMPARATOR
Intervention: Lymphocyte transformation assay for serovar C
Number of subjects: 20

Group type: COMPARATOR
Intervention: Leukocyte migration inhibition assay for serovar B
Number of subjects: 20

Group type: COMPARATOR
Intervention: Leukocyte migration inhibition assay for serovar C
Number of subjects: 20
Study: 3597861

Group type: EXPERIMENTAL
Intervention: Meat tenderizer containing the proteolytic enzyme papain
Number of subjects: 22

Group type: COMPARATOR
Intervention: Control (stings treated without tenderizer)
Number of subjects: 22
Study: 29664721

Group type: EXPERIMENTAL
Intervention: Adaptive compression
Number of subjects: 26

Group type: COMPARATOR
Intervention: Fast-acting WDRC
Number of subjects: 26
Study: 27017501

Group type: EXPERIMENTAL
Intervention: Computer-aided design of navigation template (NT)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Conventional intramedullary positioning (CIP)
Number of subjects: 36
Study: 26703671

Group type: EXPERIMENTAL
Intervention: Church-based educational intervention (three educational sessions about clinical trials and health disparities)
Number of subjects: 221

Group type: COMPARATOR
Intervention: Control (questionnaires)
Number of subjects: 221

Group type: EXPERIMENTAL
Intervention: Intervention group
Number of subjects: 221

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 221
Study: 23614393

Group type: EXPERIMENTAL
Intervention: Lacosamide 200 mg twice daily on days 1-9 with a single 25 mg dose of warfarin coadministered on day 3
Number of subjects: 16

Group type: COMPARATOR
Intervention: Warfarin alone (25 mg)
Number of subjects: 16
Study: 20429947

Group type: EXPERIMENTAL
Intervention: Online treatment program for GAD, E‐couch
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Sertraline (25-100 mg/day)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Attention control placebo, HealthWatch
Number of subjects: 120
Study: 18241758

Group type: EXPERIMENTAL
Intervention: Carotid artery stenting (CAS)
Number of subjects: 3580

Group type: COMPARATOR
Intervention: Carotid endarterectomy (CEA)
Number of subjects: 3580
Study: 17014445

Group type: EXPERIMENTAL
Intervention: Endoscopic dewaxing
Number of subjects: 100

Group type: COMPARATOR
Intervention: Microscopic dewaxing
Number of subjects: 100
Study: 14613288

Group type: EXPERIMENTAL
Intervention: Etanercept 25 mg subcutaneously twice weekly for 24 weeks
Number of subjects: 277

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 277

Group type: EXPERIMENTAL
Intervention: Etanercept 25 mg
Number of subjects: 277
Study: 10776742

Group type: EXPERIMENTAL
Intervention: High-dose aprotinin
Number of subjects: 137

Group type: EXPERIMENTAL
Intervention: Regular-dose aprotinin
Number of subjects: 137

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 137
Study: 8601640

Group type: EXPERIMENTAL
Intervention: Bradykinin infusion (27 microgram over 100 min) during normoglycemic hyperinsulinemic conditions
Number of subjects: 12

Group type: COMPARATOR
Intervention: Control leg during normoglycemic hyperinsulinemic conditions
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Bradykinin infusion (27 microgram over 100 min) in the basal state
Number of subjects: 12
Study: 1449383

Group type: EXPERIMENTAL
Intervention: Haloperidol
Number of subjects: 25

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study: 3879175

Group type: EXPERIMENTAL
Intervention: Suprofen syrup (5-7.5 mg/kg b.w., orally)
Number of subjects: 175

Group type: COMPARATOR
Intervention: L PDP ear drops (1 drop, locally)
Number of subjects: 175
Study: 30056451

Group type: EXPERIMENTAL
Intervention: Partial resin denture with 20wt% S-PRG fillers
Number of subjects: 110

Group type: COMPARATOR
Intervention: Partial resin denture without 20wt% S-PRG fillers
Number of subjects: 110
Study: 27749377

Group type: EXPERIMENTAL
Intervention: Case management intervention (details on dosage and duration not specified)
Number of subjects: 250
Study: 27382934

Group type: EXPERIMENTAL
Intervention: 20 mg intravenous hyoscine-N-butylbromide
Number of subjects: 121

Group type: COMPARATOR
Intervention: Intravenous saline solution (placebo)
Number of subjects: 121
Study: 25198222

Group type: EXPERIMENTAL
Intervention: Weight‐bearing exercise program for 20 weeks
Number of subjects: 22

Group type: COMPARATOR
Intervention: Regular activities
Number of subjects: 22
Study: 21701925

Group type: EXPERIMENTAL
Intervention: Radical cystectomy (RC)
Number of subjects: 12274

Group type: EXPERIMENTAL
Intervention: Age groups
Number of subjects: 12274

Group type: EXPERIMENTAL
Intervention: Charlson comorbidity index (CCI)
Number of subjects: 12274

Group type: EXPERIMENTAL
Intervention: Reference table for predicting POM
Number of subjects: 12274
Study: 20363190

Group type: EXPERIMENTAL
Intervention: Lithium
Number of subjects: 84

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 84
Study: 17593071

Group type: EXPERIMENTAL
Intervention: 0.1 mol/L hydrochloric acid infusion (150 mL at 15 mL/min for 10 min)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Pure water infusion (150 mL)
Number of subjects: 27
Study: 15670425

Group type: EXPERIMENTAL
Intervention: Cancer prevention intervention
Number of subjects: 197
Study: 11549532

Group type: EXPERIMENTAL
Intervention: Inhaled formoterol dry powder 12 or 24 microg twice daily
Number of subjects: 780

Group type: EXPERIMENTAL
Intervention: Ipratropium bromide 40 microg four times daily
Number of subjects: 780

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 780
Study: 9512150

Group type: EXPERIMENTAL
Intervention: One-site combined trabeculectomy and phacoemulsification
Number of subjects: 33

Group type: COMPARATOR
Intervention: Two-site combined trabeculectomy and phacoemulsification
Number of subjects: 33
Study: 7832009

Group type: EXPERIMENTAL
Intervention: Alcohol expectancy with positive alcohol beliefs
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Alcohol expectancy with negative alcohol beliefs
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Subjects who expected alcohol with positive beliefs
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Subjects who expected tonic
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Self-disclosure behavior
Number of subjects: 72
Study: 3415801

Group type: EXPERIMENTAL
Intervention: Ketanserin (40 mg every 12 hours)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 29297958

Group type: EXPERIMENTAL
Intervention: Topically applied clobetasol propionate 0.05% (mixed with 4% hydroxyethyl cellulose gel)
Number of subjects: 32

Group type: COMPARATOR
Intervention: 4% hydroxyethyl cellulose gel alone (placebo)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Topically applied clobetasol propionate 0.05%
Number of subjects: 32
Study: 26924818

Group type: EXPERIMENTAL
Intervention: Axomadol (doses ranging from 66 mg to 225 mg)
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: RR O‐demethyl metabolite
Number of subjects: 74

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 74
Study: 26285662

Group type: EXPERIMENTAL
Intervention: Acute simvastatin treatment
Number of subjects: 102
Study: 23659755

Group type: EXPERIMENTAL
Intervention: Sotrastaurin 300 mg
Number of subjects: 311

Group type: COMPARATOR
Intervention: Cyclosporine A (CsA)
Number of subjects: 311

Group type: EXPERIMENTAL
Intervention: Sotrastaurin 200 mg
Number of subjects: 311

Group type: EXPERIMENTAL
Intervention: Sotrastaurin groups
Number of subjects: 311

Group type: EXPERIMENTAL
Intervention: Sotrastaurin combined with EVR
Number of subjects: 311
Study: 20944175

Group type: EXPERIMENTAL
Intervention: CDET imaging (group B)
Number of subjects: 69

Group type: COMPARATOR
Intervention: Conventional imaging (group A)
Number of subjects: 69
Study: 18162661

Group type: EXPERIMENTAL
Intervention: Arrogance disclaimer
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Laziness disclaimer
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Selfishness disclaimer
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Disclaimers in general
Number of subjects: 0
Study: 16608770

Group type: EXPERIMENTAL
Intervention: AM3 (Inmunoferon)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study: 12755654

Group type: EXPERIMENTAL
Intervention: Quetiapine
Number of subjects: 40

Group type: COMPARATOR
Intervention: Conventional antipsychotics
Number of subjects: 40
Study: 15504993

Group type: COMPARATOR
Intervention: Physical activity >2.5 h/week
Number of subjects: 8299

Group type: COMPARATOR
Intervention: TV viewing >14 h/week
Number of subjects: 8299
Study: 10030327

Group type: EXPERIMENTAL
Intervention: Buccal midazolam
Number of subjects: 42

Group type: COMPARATOR
Intervention: Rectal diazepam
Number of subjects: 42
Study: 7559885

Group type: EXPERIMENTAL
Intervention: Intravenous GHRP-2
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Intranasal GHRP-2 (5-20 micrograms/kg per dose)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: GHRH + GHRP-2 (administered simultaneously)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Conventional agents (arginine, L-dopa/exercise, insulin)
Number of subjects: 24
Study: 2251986

Group type: EXPERIMENTAL
Intervention: Diltiazem
Number of subjects: 1067
Study: 7197960

Group type: EXPERIMENTAL
Intervention: Quinidine (492 mg quinidine-base as quinidine-bisulfate)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Quinidine formulation 1
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Quinidine formulation 2
Number of subjects: 0
Study: 28334675

Group type: EXPERIMENTAL
Intervention: Exercise intervention (n=22)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Treatment as usual (TAU) (n=20)
Number of subjects: 42
Study: 25987642

Group type: EXPERIMENTAL
Intervention: S-ketamine (0.006 mg/Kg)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Saline injection
Number of subjects: 12
Study: 22948968

Group type: EXPERIMENTAL
Intervention: Doxorubicin 30 mg/m²
Number of subjects: 743

Group type: COMPARATOR
Intervention: Daunorubicin 30 mg/m²
Number of subjects: 743

Group type: COMPARATOR
Intervention: Daunorubicin 40 mg/m²
Number of subjects: 743
Study: 20213082

Group type: EXPERIMENTAL
Intervention: Tamoxifen
Number of subjects: 334
Study: 19835126

Group type: EXPERIMENTAL
Intervention: Acupuncture at Neiguan (PC 6) without mechanical pressure
Number of subjects: 20

Group type: COMPARATOR
Intervention: Mechanical pressure of 1 kg applied at Ximen (PC 4) during and after acupuncture
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Mechanical pressure at Daling (PC 7) during acupuncture
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Mechanical pressure at Daling (PC 7) after acupuncture
Number of subjects: 20
Study: 17172317

Group type: EXPERIMENTAL
Intervention: Physical activity intervention (30-min intervals at 60% of maximum heart rate for 10 weeks)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Control group (not engaging in regular physical activity)
Number of subjects: 10
Study: 14696048

Group type: EXPERIMENTAL
Intervention: RF operators
Number of subjects: 35
Study: 11497194

Group type: COMPARATOR
Intervention: Placebo screening
Number of subjects: 140
Study: 9762161

Group type: EXPERIMENTAL
Intervention: Covered self-expanding esophageal metal stents (Cook Z Stent and Ultraflex)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Ultraflex prosthesis
Number of subjects: 32
Study: 7836510

Group type: EXPERIMENTAL
Intervention: Oestrogen-progestin add-back therapy (0.75 mg oestropipate daily + 0.7 mg norethindrone on days 1-14 each month)
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Progestin add-back therapy (10 mg norethindrone daily)
Number of subjects: 51

Group type: COMPARATOR
Intervention: Leuprolide acetate depot (3.75 mg every 4 weeks for 2 years)
Number of subjects: 51
Study: 2972550

Group type: EXPERIMENTAL
Intervention: Co-dergocrine (DA2-agonist)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Normal sodium intake (Control)
Number of subjects: 12
Study: 31916514

Group type: EXPERIMENTAL
Intervention: Short-term ART adherents (≤24 months)
Number of subjects: 3625

Group type: EXPERIMENTAL
Intervention: Longer-term ART adherents (>24 months)
Number of subjects: 3625
Study: 31669193

Group type: EXPERIMENTAL
Intervention: AS37-adjuvanted vaccine (TLR7a dose 12.5, 25, 50, 100 μg)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Control group (licensed MenC conjugate alum-adjuvanted vaccine)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: AS37-adjuvanted vaccine (TLR7a 100 μg)
Number of subjects: 80
Study: 28232209

Group type: EXPERIMENTAL
Intervention: Hypoxia group (HG): short‐term pre‐acclimatisation by the use of intermittent hypoxia 7×1h at FiO2=12.6%, equivalent to 4500m
Number of subjects: 52

Group type: COMPARATOR
Intervention: Control group (CG): sham pre‐acclimatisation 7×1h at FiO2=20.9%, equivalent to 600m
Number of subjects: 52
Study: 25833032

Group type: EXPERIMENTAL
Intervention: AmED 500 ml energy drink (ED)
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: AmED 750 ml energy drink (ED)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Alcohol
Number of subjects: 19

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study: 23499420

Group type: EXPERIMENTAL
Intervention: Slow-tempo music listening (two 1-hour daily periods)
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Slow-tempo music listening
Number of subjects: 49
Study: 21301948

Group type: EXPERIMENTAL
Intervention: HIV prevention intervention
Number of subjects: 142

Group type: COMPARATOR
Intervention: Cancer education intervention
Number of subjects: 142
Study: 19680456

Group type: EXPERIMENTAL
Intervention: Valacyclovir 1 g daily
Number of subjects: 70

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 70
Study: 17619598

Group type: EXPERIMENTAL
Intervention: Nurse practitioners in heart failure management outpatient clinics
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Nurse practitioners
Number of subjects: 0
Study: 14961155

Group type: EXPERIMENTAL
Intervention: High doses of antithrombin III (6 vials: 3000 units) once daily for 5 days or until delivery
Number of subjects: 23

Group type: COMPARATOR
Intervention: Standard doses of antithrombin III (sufficient to maintain at least 80% activity)
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: High doses of antithrombin III
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Both groups (high doses and standard doses)
Number of subjects: 23
Study: 12501151

Group type: EXPERIMENTAL
Intervention: Sucralfate (60 mg/kg/d in 4 doses via nasogastric tube)
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Ranitidine (2 mg/kg/d intravenously in 4 doses)
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Omeprazole (1 mg/kg/d intravenously in 2 doses)
Number of subjects: 160

Group type: COMPARATOR
Intervention: No treatment (control group)
Number of subjects: 160
Study: 9585041

Group type: EXPERIMENTAL
Intervention: Planar 'best septal' projection
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Planar LPO
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Tomographic radionuclide ventriculography
Number of subjects: 32
Study: 7619035

Group type: EXPERIMENTAL
Intervention: Inhalation rewarming with the Heat Treat
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Passive rewarming with a respiratory heat exchanger (HME)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Passive rewarming (Control)
Number of subjects: 8
Study: 2096602

Group type: EXPERIMENTAL
Intervention: AT877 20 mg
Number of subjects: 113

Group type: EXPERIMENTAL
Intervention: AT877 40 mg
Number of subjects: 113

Group type: EXPERIMENTAL
Intervention: AT877 60 mg
Number of subjects: 113

Group type: EXPERIMENTAL
Intervention: AT877 90 mg
Number of subjects: 113

Group type: EXPERIMENTAL
Intervention: AT877 120-180 mg
Number of subjects: 113
Study: 351537

Group type: EXPERIMENTAL
Intervention: Pseudoephedrine hydrochloride (Sudafed)
Number of subjects: 190

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 190
Study: 31498375

Group type: COMPARATOR
Intervention: Competition arm (n = 150)
Number of subjects: 602

Group type: COMPARATOR
Intervention: Support arm (n = 151)
Number of subjects: 602

Group type: COMPARATOR
Intervention: Collaboration arm (n = 150)
Number of subjects: 602

Group type: COMPARATOR
Intervention: Competition arm (n = 150) during follow-up
Number of subjects: 602

Group type: COMPARATOR
Intervention: Support arm (n = 151) during follow-up
Number of subjects: 602

Group type: COMPARATOR
Intervention: Collaboration arm (n = 150) during follow-up
Number of subjects: 602